Friday, September 16, 2022 Daily Archives

Bioprocess Considerations for Large Scale Transfection

by

This webcast features: Geddy Hamblen, Field Applications Scientist, Mirus Bio. As demand for viral vectors has grown in recent years, larger production scales are increasingly common. As processes scale, transient transfection must also scale to match. The VirusGEN® family of transfection products, developed by Mirus Bio, has been used successfully at scale in clinical manufacturing and brings unique advantages leading to higher titers and a more robust manufacturing process. In this webinar we will discuss: Challenges and solutions for transfection…

September 16, 2022

BMS confident Breyanzi capacity issues will be resolved in 2023

by

Bristol Myers Squibb will apply the same strategy used to increase Abecma supply to increase capacity for Breyanzi as it pushes back projected timelines into next year. Bristol Myers Squibb (BMS) has with its chimeric antigen receptor (CAR) T-cell therapy Breyanzi (liso-cel) “a best-in-class profile,” Christopher Boerner, EVP & chief commercialization officer told stakeholders at the Morgan Stanley Global Healthcare Conference last week. Having been approved in February 2021 for Large B-cell Lymphoma, the therapy won second-line approval for relapsed…

September 16, 2022

Takeda invests nearly $300m to expand Belgium plasma-derived therapy site

by

The close to $300 million expansion will include a manufacturing facility and a carbon net-zero emissions warehouse in Lessines, Belgium, says Takeda. The firm announced its biggest investment to date in Belgium during the 50th anniversary celebration at its manufacturing facility in Lessines and according to Takeda, the investment signals the importance of Belgium as a location for the worldwide production and distribution of plasma-derived therapies. “Takeda is building on an 80+ year pioneering legacy in producing plasma-derived therapies. The…

September 16, 2022